We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Scancell Holdings Plc | LSE:SCLP | London | Ordinary Share | GB00B63D3314 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 10.25 | 10.00 | 10.50 | 10.25 | 10.25 | 10.25 | 36,075 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 5.27M | -11.94M | -0.0129 | -7.95 | 95.1M |
Date | Subject | Author | Discuss |
---|---|---|---|
13/3/2023 12:36 | AN independent lab has found the Pfizer and Moderna Covid jabs are contaminated with double stranded DNA – 100 times the limit allowed by the European Medicines Agency (EMA). THE TRUTH IS OUT THERE !!!! | panama7 | |
13/3/2023 11:11 | Avidimab has been used (and improved) one of Seagen`s antibodies so we can presume that Pfizer will now know about it. | marcusl2 | |
13/3/2023 11:11 | ....so 10% or so above Merck's offer from last year....what will Merck do now to defend it's patent cliff on Keytruda? Surely what they need is to prove effectiveness for Keytruda in combination with something else???? | markingtime | |
13/3/2023 11:04 | Pfizer to acquire Seagen for $229 per Seagen share in cash, for a total enterprise value of approximately $43 billion | marcusl2 | |
13/3/2023 10:50 | "I just bought more" ??? A bit of a non event one way or another really. The time to worry or pay attention as *WE ALL* know, ,is when inane'n'co 'brags' about HE has employed the BUY,BUY,BUY (and HAS to HOLD) passport to FAILURE | the real lozan | |
13/3/2023 09:58 | Good call, DC, both from a strategic standpoint and a market opportunity standpoint. | markingtime | |
13/3/2023 09:48 | The percentage change from $3 to $25 is an increase of 733.33%. 17p to £1.41p would be nice! ;-) | marcusl2 | |
13/3/2023 09:47 | Interesting points made about deals and valuation in the antibody sector. Worth bearing in mind perhaps - with a risk hat on - that for all the discussion about moditope pass/fail, the other assets represent more than half of the valuation in the TD sum of parts. | wigwammer | |
13/3/2023 09:27 | Huge money in Antibodies and Bi-specifics. Gilead pledging up to $1.7 billion in biobucks for the phase 1 bispecific antibody. Lilly licenses Merus antibody therapy for up to $1.6 billion Sanofi inks US$2.5 billion deal with Adagene to develop cancer antibodies | marcusl2 | |
13/3/2023 08:43 | I just bought more | dominiccummings | |
13/3/2023 08:12 | Good to get clarification that Scancell was not with SVB Best banking with a bank that is too big to fail. Janet Yellen is back-stopping SVB’s depositors and Silicon Valley Bank's UK subsidiary has been sold to HSBC for £1 | marcusl2 | |
13/3/2023 07:47 | Scancell Holdings Plc 13 February 1637 Scancell Holdings plc ("Scancell" or the "Company") Statement re: Tulip Market Following the precipitous decline in Tulip Futures, Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer and infectious disease, can confirm that it has no investments in The Tulip Investment Bank. This announcement follows the closure of the Tulip Investment Bank by the Dutch Investment in Cultivation, Horticulture and Exotic Agriculture Department (DICHEAD) Professor Lindy Durrant. | goyathlay | |
13/3/2023 07:10 | Very good to see the pre-emptive confirmation that there is no relationship with SVB! Healtb/tech ompanies that haven't done that would have been exposed to speculation if the government hadn't just announced that it has brokered the sale of SVB UK to HSBC. | markingtime | |
12/3/2023 21:41 | Inane, interesting you talk about Mice, shame you didn't research the Animal data for the Corona vaccines. | panama7 | |
12/3/2023 11:08 | "exceptional IQ" Lord RuckRover of Camberwick Green Commented "What I have done through careful analysis" ............. have decided that ""No one can predict any single value with certainty"" giving us a range of "8p to 80p" Dates of upcoming lectures on my analysis will be presented at Colley's Mill, Bell's farm, Tripp's Dairy, and Pippin Fort. Titled "plausible nonsense" | inanaco | |
12/3/2023 08:42 | " we now have a bank full of Ruck predictions" What I have done through careful analysis, is come up with an estimate range that is realistic. No one can predict any single value with certainty as there are at this stage too many unknowns and variables. So in the short term, all I can say is that anything in the range 8p to 80p is possible. | ruckrover | |
11/3/2023 14:06 | I think stabilising disease so early on is amazing in these advanced patients. Hopefully they move on to partial response and some to complete response. The market has Scancell wrongly valued. Trinity`s cautious valuation of £300.1m, equivalent to 36.7p is closer to true value atm. | marcusl2 | |
11/3/2023 09:03 | Just been looking at Scancell data for Ovarian Cancer in the mouse model, have found it, with 80% Of mice survival ... In addition to the B16MHKO-DR4/DP4 melanoma models, we next looked at a murine ovarian tumor line (ID8MHKO-DP4) in the HLA-DP4 (cDP4) mouse model, this line expresses both vimentin and enolase (online supplementary figure 4). Those mice vaccinated with Modi-1 showed significantly higher survival than the control group (p=0.0014), indicating the potential of Modi-1 to improve survival in this indication (figure 1F). | inanaco | |
10/3/2023 19:12 | don't worry Tosh ... we now have a bank full of Ruck predictions .... not just one, but in every direction ..... it's so good, its like watching the scatter pattern of Quarks at Cern | inanaco | |
10/3/2023 19:05 | RuckRover Posted in: SCLP Posts: 5,159 Price: 13.25 No Opinion See you at 60p12 Oct 2022 14:21 FTSEBUYER, Taking on board your suggestion and to prove my optimism I have made a small purchase - 6658. My last purchase was at 14p the day it jumped to 28p so I'm hoping that history repeats itself. I think 60p is realistic in the short/medium term but £2 quite doable at some point a bit further out. | inanaco | |
10/3/2023 19:03 | RuckRover Posted in: SCLP Posts: 5,159 Price: 15.25 No Opinion RE: Crackin25 Oct 2022 16:36 I must admit, I was tempted to sell a few early when it hit 18p. This was not to minimise losses but I expected to be able to increase my holding by buying them back cheaper. Then I thought, hang on, this should be at least 24p WITHOUT the RNS and I really have no intention of selling ANY under 60p (which I think is quite achievable in the medium term once we get some MODI1 data) Holding strong! :) | inanaco | |
10/3/2023 14:18 | Rucks 15p prediction is a million miles closer than your £1 - £4 - £8, so not too sure why you're attempting to gloat... you've got absolutely ZERO to gloat about having called everything wrong and being so far out of the money. | tosh123 | |
10/3/2023 13:05 | Octopus, hopefully Modi-1 with a CPI will work even better. Blocking the binding of B7-1/B7-2 to CTLA-4 with an immune checkpoint inhibitor (anti-CTLA-4 antibody) allows the T cells to be active and to kill tumour cells The aim of such strategies can be demonstrated with checkpoint inhibitors (CPIs). Because CPIs work by removing the “brakes” on the immune system rather than directly boosting immune function, patients may also benefit from combination therapies that include immunostimulatory elements. It is here that a therapeutic vaccine could act synergistically. The vaccination induces more effective tumour-specific T cell responses, which should complement potently with CPIs. The goal is to generate a better immune response with the vaccine (or other therapy) and then to remove the suppressive effect of the tumour microenvironment with CPIs (or other immune modulators). | marcusl2 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions